Table 4 Duration of non-steroidal anti-inflammatory drugs (NSAID) use and risk of pancreatic cancer
From: Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study
Period of NSAID use | |||||||||
|---|---|---|---|---|---|---|---|---|---|
5 years before index date, excluding the year before index date | Until 1 year before index date | ||||||||
NSAID duration (days) | Cases ( n) | Controls ( n) | OR (95% CI) | Adjusted OR (95% CI) a | NSAID duration (days) | Cases ( n) | Controls ( n) | OR (95% CI) | Adjusted OR (95% CI) a |
No use | 534 | 3776 | 1.0 | 1.0 | No use | 345 | 2565 | 1.0 | 1.0 |
Category 1: 0–33.5 | 155 | 1078 | 1.02 (0.84–1.23) | 0.97 (0.79–1.18) | Category 1: 0–40.5 | 204 | 1377 | 1.10 (0.92–1.34) | 1.06 (0.87–1.28) |
Category 2: 33.6–156.5 | 152 | 1013 | 1.06 (0.88–1.29) | 1.01 (0.83–1.24) | Category 2: 40.6–156.5 | 204 | 1320 | 1.16 (0.96–1.40) | 1.09 (0.90–1.33) |
Category 3: 156.6–773 | 171 | 1044 | 1.15 (0.96–1.39) | 1.08 (0.89–1.32) | Category 3: 156.6–834 | 214 | 1346 | 1.18 (0.98–1.43) | 1.08 (0.88–1.31) |
Category 4 >773 | 129 | 1043 | 0.87 (0.70–1.07) | 0.78 (0.62–0.97) | Category 4: >834 | 174 | 1346 | 0.96 (0.79–1.18) | 0.86 (0.69–1.06) |
